We are live on ! Find out more
KYTX icon

Kyverna Therapeutics

99 hedge funds and large institutions have $321M invested in Kyverna Therapeutics in 2025 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 9

135% more capital invested

Capital invested by funds: $136M → $321M (+$184M)

100% more funds holding in top 10

Funds holding in top 10: 36 (+3)

38% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 21

32% more funds holding

Funds holding: 7599 (+24)

25.45% more ownership

Funds ownership: 52.48%77.93% (+25%)

19% less call options, than puts

Call options by funds: $967K | Put options by funds: $1.19M

Holders
99
Holders Change
+24
Holders Change %
+32%
% of All Funds
1.2%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.07%
New
36
Increased
29
Reduced
21
Closed
9
Calls
$967K
Puts
$1.19M
Net Calls
-$227K
Net Calls Change
-$1.29M
Name Holding Trade Value Shares
Change
Change in
Stake
GGI
1
GordonMD Global Investments
California
$41.3M +$32.6M +4,391,818 New
GS
2
Gilead Sciences
California
$38.8M
BCLSI
3
Bain Capital Life Sciences Investors
Massachusetts
$29.2M -$1.92M -258,370 -8%
DM
4
Deerfield Management
New York
$18.8M +$14.8M +2,000,000 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$16.7M +$3.4M +458,632 +35%
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$16.6M +$1.86M +250,418 +17%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$15.7M +$12.4M +1,666,666 New
ACM
8
AIGH Capital Management
Maryland
$14.1M +$11.1M +1,500,000 New
Morgan Stanley
9
Morgan Stanley
New York
$9.42M +$6.15M +828,292 +475%
IHG
10
Insight Holdings Group
New York
$9.3M
Balyasny Asset Management
11
Balyasny Asset Management
Illinois
$9.22M +$7.28M +980,869 New
WP
12
Woodline Partners
California
$7.94M +$4.4M +592,931 +235%
PBM
13
Propel Bio Management
California
$6.27M +$4.95M +666,666 New
MPM
14
MBB Public Markets
Illinois
$5.78M
Alyeska Investment Group
15
Alyeska Investment Group
Illinois
$5.64M +$4.45M +600,000 New
Millennium Management
16
Millennium Management
New York
$5.58M +$310K +41,734 +8%
BlackRock
17
BlackRock
New York
$5.12M +$464K +62,485 +13%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$4.87M +$3.85M +518,512 New
RA
19
RFG Advisory
Alabama
$4.18M +$3.31M +445,200 New
Citadel Advisors
20
Citadel Advisors
Florida
$2.59M +$1.91M +257,780 +1,459%
HCM
21
Heights Capital Management
California
$2.56M +$2.02M +271,822 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$2.51M -$88.5K -11,927 -4%
BNP Paribas Financial Markets
23
BNP Paribas Financial Markets
France
$2.37M +$1.62M +218,129 +641%
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
$2.24M +$268K +36,138 +18%
TD Asset Management
25
TD Asset Management
Ontario, Canada
$2.09M +$431K +58,000 +35%

KYTX Hedge Fund Activity: Q4 2025 in Review

99 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q4 2025, worth a combined $321M — up 135% from $136M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new KYTX positions and 9 closed out — a net gain of 27 holders — while 29 added to existing stakes and 21 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $14.8M. The largest seller was Franklin Resources, exiting entirely with an estimated $4.07M sold.

  • 99 institutional investors held Kyverna Therapeutics (KYTX) as of Q4 2025, up from 75 in Q3 2025.
  • Funds reported $321M of Kyverna Therapeutics stock for Q4 2025, up 135% quarter-over-quarter.
  • 36 funds opened new Kyverna Therapeutics positions in Q4 2025 and 9 closed out, a net change of +27 holders.
  • The largest Kyverna Therapeutics buyer in Q4 2025 was Deerfield Management, an estimated $14.8M added.
  • The largest Kyverna Therapeutics seller in Q4 2025 was Franklin Resources, an estimated $4.07M sold.

Based on aggregated 13F filings for Q4 2025.